Brief: vTv Therapeutics Announces Q4 Results

vTv Therapeutics

06/03/2023 23:37

March 6 (Reuters) - vTv Therapeutics Inc  VTVT.O :
    * PREPARING TO INITIATE PHASE 3 CLINICAL TRIALS OF TTP399,
AN
ADJUNCTIVE THERAPY TO INSULIN, FOR THE TREATMENT OF TYPE 1
DIABETES
    * COMPANY’S CASH POSITION AS OF DECEMBER 31, 2022, WAS $12.1
MILLION
    * NET LOSS ATTRIBUTABLE TO CO'S SHAREHOLDERS FOR THREE
MONTHS
ENDED DECEMBER 31, 2022, WAS $4.7 MILLION OR $0.06 PER BASIC
SHARE
    * Q4 EARNINGS PER SHARE VIEW $-0.06 -- REFINITIV IBES DATA

Source text for Eikon:  ID: 
Further company coverage:  VTVT.O 

 ((Reuters.Briefs@thomsonreuters.com;))